Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$19.44
-0.5%
$18.12
$16.10
$42.47
$2.44B0.672.36 million shs1.55 million shs
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$1.87
-3.1%
$2.01
$1.64
$12.51
$624.45M0.859.12 million shs6.76 million shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$21.54
-2.2%
$19.07
$14.06
$27.29
$2.42B-0.03735,337 shs678,491 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$38.03
-1.1%
$33.38
$27.12
$60.90
$2.28B2.41969,730 shs678,883 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
+1.67%+8.59%-0.26%+0.57%-47.84%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-3.02%+10.03%-18.91%-41.52%-75.19%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
+1.76%+10.96%+0.82%+45.63%+5.51%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-1.66%+0.94%+11.67%-0.98%-24.55%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
4.4321 of 5 stars
4.31.00.04.41.92.50.6
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
4.7366 of 5 stars
4.31.00.04.22.34.21.3
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
2.3241 of 5 stars
3.51.00.00.00.65.00.0
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.973 of 5 stars
3.42.00.04.42.60.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.62
Moderate Buy$39.79104.68% Upside
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
2.50
Moderate Buy$12.22553.59% Upside
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
3.00
Buy$42.8999.11% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4032.53% Upside

Current Analyst Ratings Breakdown

Latest IOVA, APLS, NAMS, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$25.00 ➝ $26.00
6/17/2025
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$42.00
6/12/2025
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00
6/10/2025
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$44.00
6/4/2025
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$42.00
6/2/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$26.00 ➝ $29.00
5/22/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$49.00 ➝ $41.00
5/16/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$17.00 ➝ $2.00
5/14/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$30.00 ➝ $20.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $8.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $10.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$781.37M3.13N/AN/A$1.84 per share10.57
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$164.07M3.81N/AN/A$2.33 per share0.80
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$47.14M51.30N/AN/A$8.20 per share2.63
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M7.28N/AN/A$8.07 per share4.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$197.88M-$1.79N/AN/AN/A-28.83%-99.19%-25.35%7/30/2025 (Estimated)
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$372.18M-$1.24N/AN/AN/A-176.49%-49.71%-39.18%8/6/2025 (Estimated)
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$241.60M-$1.88N/AN/AN/A-397.45%-37.34%-33.45%8/6/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/1/2025 (Estimated)

Latest IOVA, APLS, NAMS, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$0.44N/AN/AN/AN/AN/A
8/6/2025Q2 2025
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.52N/AN/AN/A$1.44 millionN/A
8/1/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54N/AN/AN/A$95.52 millionN/A
5/8/2025Q1 2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.25-$0.36-$0.11-$0.36$83.40 million$49.32 million
5/8/2025Q1 2025
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.45-$0.49-$0.04-$0.34$1.46 million$2.98 million
5/7/2025Q1 2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$0.36-$0.74-$0.38-$0.74$197.61 million$149.90 million
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
N/AN/AN/AN/AN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/AN/AN/AN/AN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.76
4.08
3.62
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/A
4.18
3.64
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/A
19.98
19.98
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24

Institutional Ownership

CompanyInstitutional Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
96.29%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
77.03%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
89.89%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
770125.68 million117.51 millionOptionable
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
500333.93 million299.54 millionOptionable
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
4112.27 million88.87 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Apellis Pharmaceuticals stock logo

Apellis Pharmaceuticals NASDAQ:APLS

$19.44 -0.09 (-0.46%)
Closing price 04:00 PM Eastern
Extended Trading
$19.36 -0.08 (-0.42%)
As of 04:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Iovance Biotherapeutics stock logo

Iovance Biotherapeutics NASDAQ:IOVA

$1.87 -0.06 (-3.11%)
Closing price 04:00 PM Eastern
Extended Trading
$1.88 +0.01 (+0.53%)
As of 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$21.54 -0.48 (-2.18%)
Closing price 04:00 PM Eastern
Extended Trading
$21.52 -0.02 (-0.09%)
As of 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$38.03 -0.44 (-1.14%)
Closing price 04:00 PM Eastern
Extended Trading
$38.00 -0.03 (-0.08%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.